No Name, No COVID-19 testing at home yet but quicker options coming

[Image]( EMAIL}/redirect Posted on Sunday, April 5th, 2020 By Matthew Perrone, AP Health Writer WASHINGTON (AP) — Home testing for the new coronavirus may sound like a good idea, but U.S. regulators say it's still too risky. They've stopped companies that quickly launched home-testing kits until they can show their products can accurately detect the virus. For now, the only way Americans can get tested is at hospitals, clinics or drive-thru sites, with a doctor's order. After a botched rollout, testing in the U.S. has ramped up thanks to high-volume testing machines and new rapid tests. Last week, federal officials said total tests topped 1.4 million, and labs are processing nearly 100,000 tests daily. That's the threshold many experts say is needed to track the virus. Still, testing continues to be constrained by shortages of medical supplies like gloves, masks and swabs. And the widespread drive-thru testing proposed for parking lots at chains like Walmart, Walgreens and Target has barely gotten off the ground. Meanwhile, the Food and Drug Administration is aggressively pushing new options onto the market. FASTER RESULTS Genetic tests are the gold standard for detecting COVID-19 infections. New, quicker ones are replacing the original laboratory tests that have to be manually mixed and developed. The idea behind both tests is the same: chemical solutions are used to isolate the virus from the patient sample, grab its genetic material and then reproduce it millions of times until it's detectable with a computer. New rapid tests such as the one by Abbott Laboratories automate the process, cutting the time from four to six hours to about 15 minutes. EMAIL}/redirect EMAIL}/redirect “Essentially all of the reactions are squeezed into a little cartridge, so it's a very nice, self-contained system.” said Dr. Bobbi Pritt, lab director at the Mayo Clinic in Rochester, Minnesota The cartridges from Abbott and other companies run on small, portable electronic machines found in thousands of U.S. hospitals, clinics and doctor's offices. That's expected to increase testing beyond large universities, government and commercial labs. Abbott said it plans to begin shipping 50,000 tests per day this month. U.S. officials said they'd go first to remote areas with less access to labs. For now, only a health care professional can order a coronavirus test. Under current guidelines, priority is given to people with COVID-19 symptoms who fall into several high-risk groups, including hospitalized patients, health care workers and the elderly. “If you’re not sick, you don’t need to be tested,” has been the mantra for weeks. DON'T TRY THIS AT HOME Accurately testing for coronavirus involves several steps, including carefully swabbing the nose or throat to collect a sample, placing it in a sterile tube, storing it below 46 degrees Fahrenheit and then shipping it to a lab within three days. Health officials warn a number of things could go wrong if consumers try to swab, store and ship their own samples, potentially resulting in testing errors and undetected infections. The FDA is talking to companies working on at-home kits, but they'll be required to show that their results are comparable to those of people under professional care, agency spokesman Jeremy Kahn said in a statement. Many of the proposed at-home tests aren't like home pregnancy tests — they won't provide instant results. The samples still need to go to a lab. EMAIL}/redirect EMAIL}/redirect After several companies began shipping test kits last month, the FDA quickly intervened. No home tests have been approved and the products sent to U.S. consumers were frauds, regulators said. Several companies were caught off guard including San Francisco startup Nurx, which initially built its business around prescribing birth control drugs via brief online consultations. On March 20, the company announced plans to ship 10,000 testing kits to customers for $181 each. Within 24 hours, the FDA warning went out and Nurx's plan was off. UPCOMING OPTIONS Simpler, cheaper blood tests could also have a role in tracking the virus — and possibly expanding testing to the home. The FDA is permitting companies to launch certain types of finger-prick tests that can detect whether people may have recently been infected. Instead of detecting the virus itself, these tests detect proteins called antibodies that the immune system generates to fight COVID-19. Public health experts hope that mass screening with antibody tests could eventually help track how the virus spreads and who might have built up immunity. “We have this massive epidemic on our hands and if we really want to control it through testing we need to have it more readily available and on a repeated basis — potentially every week to know who is truly positive and negative,” said Harvard University’s Dr. Michael Mina. Because the blood test is easy to perform and can be developed in 15 minutes — without laboratory equipment — some companies think it could become a viable home-testing option. Scanwell Health is seeking approval for a home test using one developed by Chinese manufacturer Innovita and deployed by the Chinese government. People who meet criteria through an online questionnaire would receive a test kit in the mail, take a blood sample and scan the test with a smartphone app. Next is an online consultation with a health professional who will deliver and interpret the results. “The entire testing process happens within the home— nothing needs to be shipped back,” said Scanwell executive Dr. Jack Jeng. ___ AP business writers Tom Murphy in Indianapolis and Anne D'innocenzio in New York contributed to this report. EMAIL}/redirect EMAIL}/redirect To get Exclusive Offers make sure you grab your cellphone (which you are probably doing right now) and join our VIP text messaging list (standard text and messaging rates may apply)to make it even easier, if you are on your cell phone now click this Button Below: [SIGN ME UP NOW]( © 2019 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as are commendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit . PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has not been compensated for this specific email, we do have advertisements in this email that we get paid if you click one of the ads (we have not investigated any of the advertisements). Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( | [Change Subscriber Options](